Characterization of Dexamethasone Containing Lipid-Based Self Nano Emulsified Drug Release System

Basit Öğe Kaydı
dc.authorscopusid56685873400
dc.authorscopusid57195263030
dc.authorscopusid16419390900
dc.contributor.authorKomesli, Yelda
dc.contributor.authorDinc, Bircan
dc.contributor.authorEge, Mehmet Ali
dc.date.accessioned2024-08-25T18:51:01Z
dc.date.available2024-08-25T18:51:01Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractLipid-based drug delivery systems are promising systems for hydrophobic drug delivery. A lipid-based self-nano-emulsified ocular drug release system has been synthesized for improving the topical ocular delivery of hydrophobic drugs. The aim is to develop preformulation that reaches the vitreal fluid, bypassing the ocular barriers, without requiring intravitreal injection. To eliminate the complications, dexamethasone (Dex) is applied in the lipid-based system called the self-nano-emulsified drug release system (DexSNEDDS). DexSNEDDS was synthesized via different oils, surfactants, and cosurfactants suitable for ophthalmic use. The resulting system was characterized by Raman, UV, FTIR Spectra, DSC, and SEM. Dex was loaded into lipids in ratios of 31.35% Labrasol/Span 80 (1:1), 31.35% transcutol, and 17.64% oleic acid. DexSNEDDS was applied to HUVEC cells, and MTT cell viability experiments were performed to determine the cytotoxicity. The size of the prepared lipid spheres was approximately 50-200 nm according to SEM images. Zeta sizer results confirm the SEM image evaluations. Differential scanning calorimeter measurements of Dex and DexSNEDDS show characteristic peaks between 221 and 261 celcius. The fingerprint region of Dex is seen in peaks between 1700 and 1600 cm(-1) in Raman spectra and at 1740, 1640, 1350, 1070, and 887 cm(-1) in FTIR spectra, and the regions emerged in the spectra of DexSNEDDS. The viability results revealed that the difference between DexSNEDDs in treated and untreated cells was not statistically significant, and DexSNEDDS is safe for in vivo testing.en_US
dc.identifier.doi10.1007/s12668-023-01090-5
dc.identifier.issn2191-1630
dc.identifier.issn2191-1649
dc.identifier.scopus2-s2.0-85151158111en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1007/s12668-023-01090-5
dc.identifier.urihttps://hdl.handle.net/11454/102436
dc.identifier.wosWOS:000959285400001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofBionanoscienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240825_Gen_US
dc.subjectDexamethasoneen_US
dc.subjectNanoemulsionen_US
dc.subjectLipid-baseden_US
dc.subjectDrugen_US
dc.subjectHUVECen_US
dc.subjectCytotoxicityen_US
dc.subjectRaman-Spectroscopyen_US
dc.subjectNanoparticlesen_US
dc.subjectDesignen_US
dc.subjectToolen_US
dc.titleCharacterization of Dexamethasone Containing Lipid-Based Self Nano Emulsified Drug Release Systemen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu